TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: White matter hyper-intensities (WMH) progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fatty acid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Experienced Major Adverse Events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Size of target skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants in Sustained Remission at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in burnout levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geometric mean titer (GMT) of HPV 16 and HPV 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Screen pass or screen refer
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in MMTMT Stimulated C-peptide AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Absolute error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variable error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quiet eye duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhaled Carbon Monoxide Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy expenditure assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Physical activity levels assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved ACR20 Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved ACR50 Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved ACR70 Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved DAS28 (CRP) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved HAQ-DI Score Improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cocaine Use/Treatment Effectiveness Score (TES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Negativity of S-100b protein and copeptin
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerated dose of MB-CART2019.1
Endpoint domain: Adverse events/effects
Primary endpoint: Safety assessment of MB-CART2019.1
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity assessment of MB-CART2019.1
Endpoint domain: Adverse events/effects
Primary endpoint: Total cost for procedure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effectiveness measured by SHORT FORM 36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Effectiveness measured by Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness measured by Stanford Health Assessment Questionnaire 20
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Effectiveness measured by SHORT FORM-6D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Measurement of the polyp detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants who experience Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Endothelium Dependent Vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of multiparametric MRI in staging bladder cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects experiencing treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects observed with a change from baseline in clinical laboratory tests, vital signs, physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects With Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Depression associated with Emotional PMS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety associated with Emotional PMS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived Stress with Emotional PMS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pulmonary blood flow variation from rest to exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrent acute pancreatitis episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Qualitative assessment of improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AAA growth over 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective benefit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of images with a score ≥ 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance at first scheduled physiotherapy session
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Direct-measured LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gait profile Score (GPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4 hours AUC of peripheral systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 4 hours AUC of energy level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 4 hours AUC of alertness level
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 4 hours AUC of nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Rankin scale (mRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of massive pneumothorax
Endpoint domain: Adverse events/effects
Primary endpoint: BMI-Z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cartilage health status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma concentrations of unconjugated Rotigotine for single-dose application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of total Rotigotine for single-dose application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) for single-dose application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levodopa Peak Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluctuation of levodopa Cmax/Cmin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Signs Score (TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rhinitis Total Symptoms Score (RTSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 15-point global rating of change questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence and severity of injection site reactions (ISRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Acute Toxicity Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Dynamic balance assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in baseline viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Viral kinetics improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total postoperative opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Knowledge of efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Difference between estimated glomerular filtration rate and creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean monthly out-of-pocket payment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage Duration With An Intragastric pH >= 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline in breathlessness when walking/climbing stairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 90-day MACCE
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in CAPS Total Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric ART Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Viral Load Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Visual Analog Scale (VAS) of subjective pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive screens for PPD
Endpoint domain: Adverse events/effects
Primary endpoint: Positive screens for IPV
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Subjects With Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Amino acid transporter expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events as assessed by the NCI CTCAE version 4.0
Endpoint domain: Adverse events/effects
Primary endpoint: CVP value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism, Myocardial Infarction and Cardiovascular Death
Endpoint domain: Mortality/survival
Primary endpoint: Cerebrospinal fluid (CSF) biomarkers related to oxidative damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Lispro Area Under the Concentration Curve Zero to 10 Hours (AUC 0-10h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in Myocardial Viability by PET/CT Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Combined End Points of Death
Endpoint domain: Mortality/survival
Primary endpoint: Serum neutralizing antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Digital Ulcer Net Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bladder Wall Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutralized Urinary Nerve Growth Factor Normalized by Urine Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Suicide Events
Endpoint domain: Adverse events/effects
Primary endpoint: Cytokine level at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence rate of mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rate of Thromboembolic events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of Hemorrhagic events
Endpoint domain: Adverse events/effects
Primary endpoint: Bone marrow doses in Gray
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to Change in Custody
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvements in Menstrual cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss following treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiac Ejection Fraction (EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: salivary Cg A hormone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in leg extensor power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to monitor medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cording following treatment for breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Best Hematological Response Categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Best Hematological Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall Best Hematologic Response and Hematologic Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improved or Maintained Hematologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative ongoing pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Femur length to mid-thigh circumference ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in WOMAC pain subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic characteristics of leukemic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of women receiving RBC units for PPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Calculated peripartum blood loss > 1000 ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Fertilization Proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Intrahepatic MRI signal assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient-perceived Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Return to sport rate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Respiratory Microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of adverse events associated with GDC-0084 after RT
Endpoint domain: Adverse events/effects
Primary endpoint: Change in dental fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Healing of RE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in cellular frataxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Islet β-cell function changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of adhesion formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fibrosis Response Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of FMT-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proper implant engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Any past year physical intimate partner violence experienced
Endpoint domain: Adverse events/effects
Primary endpoint: Past year severe physical intimate partner violence experience
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Detectable Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of A/H1N1 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Apoptosis and necroptosis of Neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measures of compliance (class attendance, frequency of home practice)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Results of post-yoga evaluations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Results of post-yoga discussion groups
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Degree of stentgraft dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of at least one episode of PSE
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in serum HCV RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in TMTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ten-words-test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in HAD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of masticatory muscular activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Tumor Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative Change in Peak Systolic Radial Strain of the Left Ventricle Inferolateral Wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Holter-ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of transthoracic echocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SARS-COV2 seroconversion prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cutaneous Tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Resolution rate of baseline comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in WOMAC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean log10 bacterial count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Regional cerebral oxygen saturation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum levels of 25-hydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment non-adherence
Endpoint domain: Adverse events/effects
Primary endpoint: Relative dose intensity (RDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Skeletal muscle fiber size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Paced Auditory Serial Audition Test (PASAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline in Berg Balance Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Functional Independence Scale score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Timed Up and Go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of treatment-emergent adverse events (TEAEs) per participant year
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with at least one TEAE per participant year
Endpoint domain: Adverse events/effects
Primary endpoint: Change in maximum concentration (Cmax) of first-line TB drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 Physical Health Summary Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning